Zobrazeno 1 - 10
of 12 829
pro vyhledávání: ''
Autor:
Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Kuniko Sunami, Takashi Kubo, Kazuki Sudo, Kayoko Tao, Makoto Hirata, Kan Yonemori, Ken Kato, Takuji Okusaka, Yuichiro Ohe, Yoshiyuki Matsui, Naoya Yamazaki, Chitose Ogawa, Akira Kawai, Yoshitaka Narita, Minoru Esaki, Noboru Yamamoto
Publikováno v:
Cancer Science. 113:4300-4310
Previous clinical trials indicate that 10%-25% of patients received genomically matched therapy after comprehensive genomic profiling (CGP) tests. However, the clinical utility of CGP tests has not been assessed in clinical practice. We assessed the
Publikováno v:
Cancer Causes & Control. 33:1161-1172
Purpose To quantitatively evaluate contributions of trends in incidence, relative survival, and stage at diagnosis to the dynamics in the prevalence of major cancers (lung, prostate, colon, breast, urinary bladder, ovaries, stomach, pancreas, esophag
Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery
Autor:
Kelsey L. Corrigan, Shuangshuang Fu, Ying‐Shiuan Chen, Kelsey Kaiser, Michael Roth, Susan K. Peterson, Ya‐Chen T. Shih, Reshma Jagsi, Sharon H. Giordano, Robert J. Volk, K. Robin Yabroff, Mathew P. Banegas, Chiara Acquati, Rena M. Conti, Hilary Y. Ma, Kimberly Ku, Y. Nancy You, Grace L. Smith
Publikováno v:
Cancer, vol 128, iss 13
Cancer
Cancer
BackgroundYoung adults and other working-age adults with cancer are at risk for cancer-related financial toxicity (FT), including material hardships, depletion of coping resources, and psychological burden. This study compares FT domains in young adu
Publikováno v:
Journal of Clinical Oncology. 40:1102-1110
PURPOSE Generic competition can be delayed if brand-name manufacturers obtain additional patents on supplemental uses. The US Food and Drug Administration allows generic drug manufacturers to market versions with skinny labels that exclude patent-pro
Autor:
Kathryn Tremble, Louis Fox, Charlotte Moss, Beth Russell, Haleema Aljazzaf, Finola Higgins, Bill Dann, Vikash Jogia, Graham Roberts, Anne Rigg, Saoirse Dolly, Mieke Van Hemelrijck
Publikováno v:
Future Oncology
Objective: The authors monitored positivity rates of asymptomatic SARS-CoV-2 tests during the second wave of COVID-19 at Guy's Cancer Centre. Methods: Logistic regression was used to investigate factors associated with asymptomatic COVID positivity r
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:1363-1374
Purpose We aim to assess attitudes toward a COVID-19 vaccine and vaccination status in cancer patients and to explore additional factors such as the level of information and comprehensibility and accessibility of this information, anxiety symptoms in
Autor:
Becky White, Meena Rafiq, Arturo Gonzalez-Izquierdo, Willie Hamilton, Sarah Price, Georgios Lyratzopoulos
Publikováno v:
British Journal of Cancer. 126:1627-1636
Background The management of adults presenting with fatigue presents a diagnostic challenge, particularly regarding possible underlying cancer. Methods Using electronic health records, we examined cancer risk in patients presenting to primary care wi
Autor:
Hongseok Yun, Seung Hong Choi, Ka Young Lim, Seung-Ki Kim, Yumi Shim, Tae Min Kim, Jin-Woo Park, Hyunhee Kim, Jeongwan Kang, Sung Hye Park, Chul-Kee Park, Kwanghoon Lee, Jae Kyung Won
Publikováno v:
Laboratory Investigation; a Journal of Technical Methods and Pathology
Mismatch repair-deficient (MMRD) brain tumors are rare among primary brain tumors and can be induced by germline or sporadic mutations. Here, we report 13 MMRD-associated (9 sporadic and 4 Lynch syndrome) primary brain tumors to determine clinicopath
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Publikováno v:
Future Oncology
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test